Akums Drugs approved acquisition of Oriflame India; reports robust Q1 FY27 performance with 13.9% YoY Revenue growth

Published at : Sep 15, 2026 11:31 AM (IST)

Total Views : 9

Akums Drugs approved acquisition of Oriflame India; reports robust Q1 FY27 performance with 13.9% YoY Revenue growth

The Print Times

Akums Drugs and Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organization (CDMO), announced its consolidated financial results for the quarter ended June 30, 2026, marking a strong start to FY27. The Company delivered healthy growth in revenue, operating profitability and PAT, supported by continued momentum in its CDMO business, improved operating performance and healthy customer demand.

Akums Drugs & Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (“CDMO”) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, Akums own the intellectual property for the manufacturing processes of several of our formulations, and its core business is focused on providing end-to-end product development and manufacturing solutions to its clients.

Akums reported operating revenue of Rs. 1,167 crore in Q1 FY27, registering a 13.9% year-on-year growth compared with Rs. 1,024 crore in Q1 FY26. EBITDA increased 35.4% year-on-year to Rs. 175 crore, with EBITDA margin improving to 15.0% from 12.6%. PAT stood at ₹101 crore, compared with Rs. 65 crore in the corresponding quarter last year. PAT margin also improved to 8.4% from 6.2%.

Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, "FY27 has begun on a strong and encouraging note. The consistent performance of CDMO showcases healthy demand environment as well as our clients' trust in Akums as the preferred manufacturing partner." 

Mr. Jain, added, "We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable growth in the years ahead."

Acquisition of Oriflame India

Akums Drugs and Pharmaceuticals Limited at its Board Meeting held on 23rd July, 2026 has, inter alia, considered and approved acquisition of Oriflame India Private Limited’s manufacturing business for total consideration of INR 56 Crore. It includes two manufacturing plants at Roorkee, Uttarakhand and Noida, Uttar Pradesh, along with a leased warehouse situated at Noida.

Cosmetics is a fast-growing opportunity in India and this will mark as Akums’ entry into color cosmetics; and expand its presence in skincare & wellness products as well. The trademark and marketing of Oriflame’s products in India is not part of this transaction.

The object is to acquire the manufacturing business of Oriflame India Private Limited situated at two locations i.e. Roorkee, Uttarakhand and Noida, Uttar Pradesh, along with a leased warehouse situated at Noida. This will expand Akums’ manufacturing capacity as well as capability of cosmetic and wellness products for Indian as well as global markets

Acquisition is expected to be completed by 31st August 2026.

Published at : Sep 15, 2026 11:31 AM (IST)

Total Views : 9